ERBB2 and breast carcinoma: Of these, according to the latest data from the Surveillance, Epidemiology, and End Results Program (SEER) database, HER2-positive breast cancer accounts for about 14-15% of all breast cancer patients, which are highly aggressive and have a poor prognosis.